Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

1,102 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Randomized Double-Blind Phase II Study of Maintenance Pembrolizumab Versus Placebo After First-Line Chemotherapy in Patients With Metastatic Urothelial Cancer.
Galsky MD, Mortazavi A, Milowsky MI, George S, Gupta S, Fleming MT, Dang LH, Geynisman DM, Walling R, Alter RS, Kassar M, Wang J, Gupta S, Davis N, Picus J, Philips G, Quinn DI, Haines GK 3rd, Hahn NM, Zhao Q, Yu M, Pal SK. Galsky MD, et al. Among authors: pal sk. J Clin Oncol. 2020 Jun 1;38(16):1797-1806. doi: 10.1200/JCO.19.03091. Epub 2020 Apr 9. J Clin Oncol. 2020. PMID: 32271672 Free PMC article. Clinical Trial.
Overcoming chemotherapy resistance in prostate cancer.
Madan RA, Pal SK, Sartor O, Dahut WL. Madan RA, et al. Among authors: pal sk. Clin Cancer Res. 2011 Jun 15;17(12):3892-902. doi: 10.1158/1078-0432.CCR-10-2654. Clin Cancer Res. 2011. PMID: 21680545 Free PMC article.
Differentiating mTOR inhibitors in renal cell carcinoma.
Pal SK, Quinn DI. Pal SK, et al. Cancer Treat Rev. 2013 Nov;39(7):709-19. doi: 10.1016/j.ctrv.2012.12.015. Epub 2013 Feb 21. Cancer Treat Rev. 2013. PMID: 23433636 Free PMC article. Review.
Optimizing systemic therapy for bladder cancer.
Pal SK, Milowsky MI, Plimack ER. Pal SK, et al. J Natl Compr Canc Netw. 2013 Jul;11(7):793-804. doi: 10.6004/jnccn.2013.0101. J Natl Compr Canc Netw. 2013. PMID: 23847217 Review.
Novel tyrosine kinase inhibitors for renal cell carcinoma.
Dorff TB, Pal SK, Quinn DI. Dorff TB, et al. Among authors: pal sk. Expert Rev Clin Pharmacol. 2014 Jan;7(1):67-73. doi: 10.1586/17512433.2014.862496. Epub 2013 Dec 2. Expert Rev Clin Pharmacol. 2014. PMID: 24308791 Review.
A phase I study of cabozantinib (XL184) in patients with renal cell cancer.
Choueiri TK, Pal SK, McDermott DF, Morrissey S, Ferguson KC, Holland J, Kaelin WG, Dutcher JP. Choueiri TK, et al. Among authors: pal sk. Ann Oncol. 2014 Aug;25(8):1603-8. doi: 10.1093/annonc/mdu184. Epub 2014 May 14. Ann Oncol. 2014. PMID: 24827131 Free PMC article. Clinical Trial.
Cisplatin-based first-line therapy for advanced urothelial carcinoma after previous perioperative cisplatin-based therapy.
Necchi A, Pond GR, Giannatempo P, Di Lorenzo G, Eigl BJ, Locke J, Pal SK, Agarwal N, Poole A, Vaishampayan UN, Niegisch G, Hussain SA, Singh P, Bellmunt J, Sonpavde G. Necchi A, et al. Among authors: pal sk. Clin Genitourin Cancer. 2015 Apr;13(2):178-84. doi: 10.1016/j.clgc.2014.08.010. Epub 2014 Sep 23. Clin Genitourin Cancer. 2015. PMID: 25450035 Free PMC article.
1,102 results